default

3

Envarsus XR®

ENVARSUS XR is a once-daily, extended-release tacrolimus formulation indicated for the prophylaxis of organ rejection in de novo kidney transplant patients in combination with other immunosuppressants. It is marketed by Veloxis Pharmaceuticals in the United States.

TERIBONE™ (teriparatide acetate)

Teribone™ is a human parathyroid hormone preparation that facilitates bone formation, for the indication of osteoporosis with weekly or twice weekly subcutaneous injections.

RECLAST™ (zoledronic acid)

Reclast™ is a bisphosphonate agent that suppresses bone resorption, for the treatment of osteoporosis with once-a-year intravenous infusion. Reclast™ is a registered trademark of Novartis.

RECOMODULIN™ (thrombomodulin alpha)

Recomodulin™ is a thrombomodulin agent produced through genetic engineering, indicated for the treatment of disseminated intravascular coagulation (DIC) associated with malignant tumors, infectious diseases, etc.

KEVZARA® (sarilumab)

Kevzara® is a human monoclonal antibody that blocks the action of IL-6, for the treatment of rheumatoid arthritis. Kevzara® is a registered trademark of Sanofi Biotechnology.

PLAQUENIL® (hydroxychloroquine sulfate)

Plaquenil® is an immunomodulator indicated for the treatment of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). Plaquenil® is a registered trademark of Sanofi-Aventis U.S.

DOPTELET® (avatrombopag maleate)

Doptelet® is a thrombopoietin receptor agonist, which is an agent for improving thrombocytopenia in patients with chronic liver disease who are scheduled to undergo an invasive procedure. Asahi Kasei Therapeutics obtained exclusive distribution rights in Japan for Doptelet® for thrombocytopenia associated with chronic liver disease from Swedish Orphan Biovitrum Japan Co., Ltd.

CRESEMBA™（isavuconazonium sulfate）

Cresemba™ is an azole antifungal drug for fungal infections, such as Aspergillosis (invasive aspergillosis, chronic progressive pulmonary aspergillosis, simple pulmonary aspergilloma), Mucormycosis, and Cryptococcosis (pulmonary cryptococcosis, disseminated cryptococcosis (including cryptococcal meningitis))

EMPAVELI® (pegcetacoplan)

Empaveli® is a PEGylated peptide1 inhibiting the function of complement protein C3 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Asahi Kasei Therapeutics obtained exclusive distribution rights in Japan for Empaveli® for PNH from Swedish Orphan Biovitrum Japan Co., Ltd.